05d365ce-b1d0-46af-b74a-b254f2c7de8e
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- ALLOGRAFT_REJECTION+0.300
- IL6_JAK_STAT3_SIGNALING+0.300
- INTERFERON_GAMMA_RESPONSE+0.300
- MYC_TARGETS_V1+0.300
- PROTEIN_SECRETION+0.300
- APOPTOSIS+0.200
- CHOLESTEROL_HOMEOSTASIS+0.200
- COAGULATION+0.200
- COMPLEMENT+0.200
Top 10 suppressed
- KRAS_SIGNALING_DN-0.200
- HEDGEHOG_SIGNALING-0.100
- HYPOXIA-0.100
- TNFA_SIGNALING_VIA_NFKB-0.100
- WNT_BETA_CATENIN_SIGNALING-0.100
- ANGIOGENESIS+0.000
- APICAL_JUNCTION+0.000
- APICAL_SURFACE+0.000
- BILE_ACID_METABOLISM+0.000
- GLYCOLYSIS+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E7-A7DV-01A-11R-A33J-07 | — | — | 0.822 |
| 2 | MNG1200 | — | — | 0.811 |
| 3 | MNG485 | — | — | 0.809 |
| 4 | SJEPD030367_D2.RNA-Seq | EPN | Supratentorial EPN | 0.797 |
| 5 | F42071CA-8794-4C79-8B02-8D48C70E8BA1 | — | — | 0.784 |
| 6 | SRR10900566 | — | — | 0.782 |
| 7 | SJEPD030229_D1.RNA-Seq | EPN | Supratentorial EPN | 0.782 |
| 8 | SRR6013499 | — | cohortA1 | 0.779 |
| 9 | SRR8942937 | — | — | 0.779 |
| 10 | SRR1313147 | — | E | 0.777 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |